STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has STAAR Surgical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STAA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: STAA's weekly volatility (10%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: STAA exceeded the US Medical Equipment industry which returned 40.4% over the past year.
Return vs Market: STAA exceeded the US Market which returned 56.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is STAAR Surgical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Much Are STAAR Surgical Company (NASDAQ:STAA) Insiders Taking Off The Table?
1 month ago | Simply Wall StAre Institutions Heavily Invested In STAAR Surgical Company's (NASDAQ:STAA) Shares?
2 months ago | Simply Wall StDo Its Financials Have Any Role To Play In Driving STAAR Surgical Company's (NASDAQ:STAA) Stock Up Recently?
Is STAAR Surgical undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: STAA ($115.95) is trading above our estimate of fair value ($40.01)
Significantly Below Fair Value: STAA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: STAA is poor value based on its PE Ratio (894.3x) compared to the US Medical Equipment industry average (50.2x).
PE vs Market: STAA is poor value based on its PE Ratio (894.3x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: STAA is poor value based on its PEG Ratio (14.5x)
Price to Book Ratio
PB vs Industry: STAA is overvalued based on its PB Ratio (27.3x) compared to the US Medical Equipment industry average (5x).
How is STAAR Surgical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STAA's forecast earnings growth (61.8% per year) is above the savings rate (2%).
Earnings vs Market: STAA's earnings (61.8% per year) are forecast to grow faster than the US market (18.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: STAA's revenue (20.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: STAA's revenue (20.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STAA's Return on Equity is forecast to be high in 3 years time
How has STAAR Surgical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STAA has high quality earnings.
Growing Profit Margin: STAA's current net profit margins (3.6%) are lower than last year (9.3%).
Past Earnings Growth Analysis
Earnings Trend: STAA has become profitable over the past 5 years, growing earnings by 68.3% per year.
Accelerating Growth: STAA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: STAA had negative earnings growth (-57.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (10.1%).
Return on Equity
High ROE: STAA's Return on Equity (3%) is considered low.
How is STAAR Surgical's financial position?
Financial Position Analysis
Short Term Liabilities: STAA's short term assets ($216.4M) exceed its short term liabilities ($41.2M).
Long Term Liabilities: STAA's short term assets ($216.4M) exceed its long term liabilities ($19.0M).
Debt to Equity History and Analysis
Debt Level: STAA's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: STAA's debt to equity ratio has reduced from 10.7% to 0.7% over the past 5 years.
Debt Coverage: STAA's debt is well covered by operating cash flow (1519.3%).
Interest Coverage: STAA earns more interest than it pays, so coverage of interest payments is not a concern.
What is STAAR Surgical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate STAA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STAA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STAA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STAA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STAA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Caren Mason (66 yo)
Ms. Caren L. Mason has been the Chief Executive Officer and President of STAAR Surgical Company since March 1, 2015. Ms. Mason served as the Chief Executive Officer of Verinata Health, Inc. from April 2011...
CEO Compensation Analysis
Compensation vs Market: Caren's total compensation ($USD3.62M) is below average for companies of similar size in the US market ($USD6.40M).
Compensation vs Earnings: Caren's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: STAA's management team is considered experienced (4.1 years average tenure).
Experienced Board: STAA's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: STAA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
STAAR Surgical Company's company bio, employee growth, exchange listings and data sources
- Name: STAAR Surgical Company
- Ticker: STAA
- Exchange: NasdaqGM
- Founded: 1982
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$5.398b
- Shares outstanding: 46.55m
- Website: https://www.staar.com
Number of Employees
- STAAR Surgical Company
- 25651 Atlantic Ocean Drive
- Lake Forest
- United States
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 22:08|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.